AB2 Bio sign agreement with Nippon for for ultra-rare disease
28 Jan 2025 //
GLOBENEWSWIRE
AB2 Bio Completes Enrolment in Pivotal Phase 3 Trial of Tadekinig alfa
07 Mar 2023 //
GLOBENEWSWIRE
28 Jan 2025 //
GLOBENEWSWIRE
07 Mar 2023 //
GLOBENEWSWIRE